Pharmaceutical Commerce: October 2025 Interactive Digital Edition

Jon Hamrick, partner at Curatio Advisors, discusses how product attributes, company size and stakeholder alignment shape pharma commercialization strategy.

The rule targets PBMs, but rebate, price protection and formulary deals they strike with drugmakers will be disclosed to plan fiduciaries and open to audit.

DOL's final rule requires PBMs to disclose rebates and formulary incentives to large self-insured plans for plan years beginning on or after July 1, 2027.

In this week’s Pharma Pulse, GoodRx expands an employer offering built on manufacturer pricing for GLP-1 obesity drugs, a federal judge declines to block Lilly’s comparative Zepbound ads, and the PBM industry’s trade group turns the vertical integration debate toward drug wholesalers.

Why outdated paper prescribing information is creating unnecessary cost, complexity and friction across a modern pharmaceutical supply chain.

At LogiPharma USA 2026, Mark Talens explains how end-to-end visibility lets pharma see its value chain across functions, and where supply chain monitoring is headed next.

EVERSANA is folding Estima Scientific's AI-powered HEOR tools into its market access offerings as its CEO says evidence planning must start earlier.

Walgreens adds GLP-1 coverage navigation, Medicare Bridge support and pharmacist outreach to its virtual weight management service.